NSE - Delayed Quote INR

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)

1,788.00

-38.35

(-2.10%)

At close: January 10 at 3:29:59 PM GMT+5:30

India flags quality issues with some widely used antacids and paracetamol

BENGALURU (Reuters) -India's drug regulator has found more than 50 drugs, including some batches of widely used antacids and paracetamol, to be substandard or fake, according to government documents. The regulator, Central Drugs Standard Control Organisation, releases a monthly list of substandard or fake medicines sold in the country after routine tests across the country by multiple agencies. The regulator found some drugs as "not of standard quality", including a batch each of Alkem Laboratories' popular antacid Pan-D, Hetero's anti-infective Cepodem and Shelcal, a vitamin and calcium tablet brand made by privately-owned Pure & Cure Healthcare, and several antibiotics, according to the lists for August.

Reuters 3 months ago

SUNPHARMA.NS
-2.10%
Sun Pharma and Moebius gain FDA fast track for osteoarthritis drug

MM-II reduces joint friction and wear, thereby alleviating pain.

Pharmaceutical Technology 4 months ago

SUNPHARMA.NS
-2.10%
India stocks higher at close of trade; Nifty 50 up 0.05%

Investing.com – India stocks were higher after the close on Friday, as gains in the Auto, IT and Capital Goods sectors led shares higher.

Investing.com 4 months ago

SUNPHARMA.NS
-2.10%
Pharmazz Inc. and Sun Pharma entered into an agreement under which Sun Pharma will invest up to $15 Million in Pharmazz, Inc.

Strategic equity investment of $15 M to support completion of Pharmazz's pivotal Phase 3 study for Sovateltide to treat patients with acute cerebral ischemic strokeExpansion of the exclusive license agreement with Sun Pharma for marketing and distribution of Sovateltide in India to certain additional Emerging Market countries WILLOWBROOK, Ill., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Pharmazz, Inc. (“Pharmazz” or the “Company”), a biopharmaceutical company focused on developing and commercializing nov

GlobeNewswire 4 months ago

SUNPHARMA.NS
-2.10%
SUNPHARMA.BO
FDA approves Sun Pharma’s JAK inhibitor for alopecia

The FDA approval is based on data gathered from two Phase III studies where over 30% of the patients gained 80% or more coverage of scalp hair.

Pharmaceutical Technology 5 months ago

SUNPHARMA.NS
-2.10%
Sun Pharma’s Phase I GL0034 study shows weight loss efficacy and lipid reduction

Sun Pharma says GL0034’s additional ability to lower lipid profiles may set it apart from other weight loss treatments.

Clinical Trials Arena 6 months ago

SUNPHARMA.NS
-2.10%
Philogen and Sun Pharma seek EMA approval for melanoma therapy

In a Phase III trial, Nidlegy demonstrated to significantly reduce the relapse or death risk by 41% versus control.

Pharmaceutical Technology 7 months ago

SUNPHARMA.NS
-2.10%
30 Most Valuable Drug Companies in 2024

In this article, we will take a look at the 30 most valuable drug companies in 2024. If you want to skip our detailed analysis of the pharmaceutical drugs market, you can go directly to 5 Most Valuable Drug Companies in 2024. The Global Pharmaceutical Drugs Market According to a report by The Business Research […]

Insider Monkey 10 months ago

ABBV

NVO

LLY
India's Sun Pharma to buy remaining stake in Israeli unit Taro for about $348 million

The Indian drugmaker, which currently owns about 78.5% stake in Taro, had offered to buy its remaining stake for $38 per share in May. Upon completion of the merger, which is expected to close in the first half of the year, Taro would become a privately held company and will be delisted from the New York Stock Exchange, the companies said. The U.S. government had in November dismissed charges against a former Taro executive who was accused of conspiring to fix generic drug prices between 2013 and 2015.

Reuters 11 months ago

TARO

SUNPHARMA.NS
-2.10%

Performance Overview

Return	SUNPHARMA.NS	S&P BSE SENSEX
YTD	-5.09%	-1.11%
1-Year	+36.25%	+8.39%
3-Year	+122.49%	+29.52%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)

India flags quality issues with some widely used antacids and paracetamol

Sun Pharma and Moebius gain FDA fast track for osteoarthritis drug

India stocks higher at close of trade; Nifty 50 up 0.05%

Pharmazz Inc. and Sun Pharma entered into an agreement under which Sun Pharma will invest up to $15 Million in Pharmazz, Inc.

FDA approves Sun Pharma’s JAK inhibitor for alopecia

Sun Pharma’s Phase I GL0034 study shows weight loss efficacy and lipid reduction

Philogen and Sun Pharma seek EMA approval for melanoma therapy

30 Most Valuable Drug Companies in 2024

India's Sun Pharma to buy remaining stake in Israeli unit Taro for about $348 million

Performance Overview